13F Holdings
中文EN

IMA ImageneBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1835579 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.2%
TTM EPS YoY83.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-32.3%
ROA-28.6%
ROIC (approx.)-98.2%
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio16.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$800,000$3.50M$9.16M$15.62M$30.98M
R&D expense$28.52M$32.11M$59.65M$64.32M$47.11M
SG&A expense$20.73M$8.39M$24.93M$22.20M$18.02M
Operating income-$48.45M-$37.00M-$75.42M-$70.90M-$34.14M
Pretax income-$45.70M-$36.55M-$68.33M-$68.77M—
Income tax-$350,000$13,000-$162,000$0$0
Net income-$45.35M-$36.57M-$68.17M-$68.77M-$34.12M
EBITDA-$48.05M-$35.90M-$74.40M-$70.15M-$33.59M
EPS (basic)-9.64-22.10-1.63-1.90-1.22
EPS (diluted)-9.64-22.10-1.63-1.90-1.22
Weighted avg. shares (diluted)—48.26M41.74M36.19M27.98M
Balance sheet
Cash & equivalents$94.53M$12.12M$15.32M$60.79M$233.09M
Short-term investments$40.82M$0$55.57M$97.03M—
Current assets$140.29M$12.47M$178.66M$160.01M$236.52M
PP&E, net$0$8,000$2.33M$3.21M$2.44M
Total assets$152.98M$15.92M$192.09M$172.26M$247.88M
Current liabilities$11.23M$17.21M$14.21M$21.50M$27.19M
Short-term debt$0$7.50M———
Total liabilities$19.84M$17.45M$22.34M$25.29M$40.00M
Shareholders' equity$133.14M-$160.56M-$126.11M$146.97M$207.88M
Shares outstanding—48.26M48.26M36.26M35.98M
Cash flow statement
Operating cash flow-$47.84M-$21.32M-$79.74M-$74.11M-$60.25M
Capital expenditure——$414,000$1.43M$1.76M
Free cash flow——-$80.16M-$75.54M-$62.01M
Investing cash flow-$5.81M$11.12M$64.14M-$99.28M-$1.76M
Financing cash flow$135.47M$6.91M$75.98M$1.09M$131.74M
Depreciation & amortization$400,000$1.10M$1.02M$751,000$544,000
Stock-based compensation$15.39M$0$7.63M$7.53M$5.18M
Share buybacks——$663,000——

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.